FLT3 and acute myeloid leukemia: While conventional chemotherapy, with or without SCT, is still pivotal in curative treatment and/or disease control for AML because of its high proliferation intensity, molecular targeted approaches (e.g., GO and FLT3 inhibitors) remain a practical alternative, especially for patients with relapsed/refractory or intolerable AML to intensive treatment.